CSF levels in patients with CNS lymphoma who were treated intravenously with rituximab plus high-dose methotrexate or Ara-C
| Patient no. . | Week . | Serum rituximab . | CSF rituximab . |
|---|---|---|---|
| 1 | 4 | 345.7 μg/mL | 0.44 μg/mL |
| 2 | 8 | — | 0.6 μg/mL |
| 3 | 1 | 355.4 μg/mL | 0.48 μg/mL |
| 4* | 1 | 273.8 μg/mL | LTR† |
| Patient no. . | Week . | Serum rituximab . | CSF rituximab . |
|---|---|---|---|
| 1 | 4 | 345.7 μg/mL | 0.44 μg/mL |
| 2 | 8 | — | 0.6 μg/mL |
| 3 | 1 | 355.4 μg/mL | 0.48 μg/mL |
| 4* | 1 | 273.8 μg/mL | LTR† |
Patients received rituximab at 375 mg/m2intravenously weekly for 8 treatments. Rituximab levels were determined in serum and atraumatic CSF specimens collected simultaneously at the completion of the rituximab infusion.
— indicates not available.
Patient no. 4 had malignant CSF cytology but no contrast-enhancing lesions on MRI.
The assay result was less than the reportable limit.